benefit
treatment
antivir
therapi
sever
adenoviru
adv
pneumonia
well
establish
describ
clinic
characterist
treatment
outcom
earli
cidofovir
treatment
sever
adv
pneumonia
nonimmunocompromis
patient
retrospect
review
medic
record
patient
diagnos
sever
adv
pneumonia
total
seven
nonimmunocompromis
patient
sever
adv
pneumonia
identifi
isol
type
n
human
patient
progress
respiratori
failur
lobar
consolid
without
patchi
ground
glass
opac
three
patient
requir
vasopressor
mechan
ventil
patient
abnorm
laboratori
find
includ
leukopenia
thrombocytopenia
elev
liver
enzym
admiss
patient
receiv
antivir
therapi
cidofovir
median
time
admiss
cidofovir
administr
h
median
time
onset
symptom
cidofovir
administr
day
cidofovir
administr
complet
symptomat
improv
occur
median
day
radiograph
resolut
occur
median
day
consequ
patient
complet
improv
without
complic
data
suggest
earli
administr
cidofovir
cours
treatment
respiratori
failur
result
adv
pneumonia
nonimmunocompromis
patient
could
treatment
strategi
worth
consid
especi
case
infect
adenovirus
adv
nonenvelop
doublestrand
dna
virus
caus
diseas
upper
lower
respiratori
gastrointestin
ocular
system
respiratori
infect
caus
adv
nonimmunocompromis
patient
usual
mild
selflimit
contrast
immunocompromis
patient
adv
infect
dissemin
result
consider
mortal
rate
despit
low
incid
seriou
ill
nonimmunocompromis
patient
levin
et
al
report
fatal
adv
pneumonia
previous
healthi
adult
sporad
case
sever
respiratori
diseas
nonimmunocompromis
adult
report
sinc
report
includ
sever
outbreak
adv
respiratori
infect
previous
healthi
adult
vulner
popul
resid
mental
health
care
center
militari
recruit
previou
investig
describ
clinic
characterist
sever
adv
pneumonia
distinct
caus
agent
reveal
sever
adv
serotyp
associ
sever
diseas
state
howev
effort
influenc
overal
clinic
outcom
case
sever
adv
pneumonia
current
approv
antivir
agent
treatment
sever
adv
pneumonia
limit
data
clinic
respons
antivir
therapi
immunocompromis
patient
avail
institut
militari
hospit
highest
referr
rate
south
korea
encount
sever
case
adv
pneumonia
annual
sever
case
thu
aim
produc
favor
outcom
appli
antivir
therapi
upon
confirm
diagnosi
sever
adv
pneumonia
present
studi
describ
detail
clinic
characterist
favor
treatment
outcom
nonimmunocompromis
adult
experienc
sever
adv
pneumonia
receiv
earli
cidofovir
administr
retrospect
review
medic
record
consecut
patient
diagnos
adv
pneumonia
decemb
june
arm
forc
capit
hospit
bed
referr
militari
hospit
gyeonggi
provinc
south
korea
diagnosi
adv
pneumonia
consid
certain
associ
follow
lower
respiratori
andor
system
symptom
lung
infiltr
chest
radiographi
comput
tomographi
ct
scan
evid
adv
infect
identifi
posit
multiplex
polymeras
chain
reaction
pcr
adv
lower
respiratori
tract
sampl
sputum
bronchoalveolar
lavag
bal
fluid
nonimmunocompromis
adult
patient
fulfil
criteria
sever
communityacquir
pneumonia
set
infecti
diseas
societi
americaamerican
thorac
societi
consensu
guidelin
admit
intens
care
unit
progress
respiratori
failur
defin
partial
pressur
arteri
oxygen
pao
fraction
inspir
oxygen
fio
ratio
mmhg
andor
tachypnea
respir
rate
breathsmin
includ
analysi
criteria
sever
communityacquir
pneumonia
requir
admiss
intens
care
unit
one
major
criteria
three
minor
criteria
major
criteria
includ
invas
mechan
ventil
requir
vasopressor
due
septic
shock
minor
criteria
includ
respiratori
rate
pao
fio
ratio
mmhg
multilobar
pneumonia
chest
radiograph
decreas
level
conscious
blood
urea
nitrogen
mgdl
white
blood
cell
platelet
core
temperatur
hypotens
requir
aggress
fluid
therapi
institut
review
board
arm
forc
capit
hospit
approv
studi
permit
review
public
patient
record
data
studi
patient
analyz
anonym
requir
inform
consent
individu
patient
waiv
given
retrospect
natur
studi
find
includ
leukopenia
extrapulmonari
symptom
suspect
atyp
pneumonia
underw
thorough
examin
infecti
etiolog
investig
use
peripher
blood
sputum
bal
fluid
util
techniqu
stain
microbiolog
cultur
bacteria
mycobacterium
tuberculosi
multiplex
real
time
pcr
test
respiratori
bacteri
agent
includ
streptococcu
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
bordetella
multiplex
real
time
pcr
test
respiratori
virus
nucleic
acid
extract
perform
magna
pure
lc
roch
diagnost
mannheim
germani
use
magna
pure
lc
nucleic
acid
isol
kit
roch
diagnost
accord
manufactur
instruct
fifti
microlit
clinic
sampl
use
nucleic
acid
extract
elut
elut
buffer
multiplex
realtim
pcr
perform
screen
commonli
isol
respiratori
viral
pathogen
includ
adenoviru
rhinoviru
influenza
viru
ab
respiratori
syncyti
viru
ab
bocaviru
coronaviru
parainfluenza
viru
metapneumoviru
use
realq
rv
detect
kit
biosewoom
seoul
korea
roch
light
cycler
ii
instrument
roch
diagnost
mannheim
germani
accord
manufactur
instruct
presenc
specif
viral
sequenc
reaction
detect
increas
fam
vic
fluoresc
relev
duallabel
probe
five
primerprob
set
use
detect
respiratori
virus
serotyp
humanadvposit
sampl
evalu
sequenc
analysi
use
partial
hexon
genom
region
cidofovir
mylan
institut
initi
upon
confirm
adv
infect
cidofovir
dosag
weekli
administr
combin
oral
probenecid
hydrat
consist
l
normal
salin
cidofovir
infus
l
immedi
thereaft
prevent
renal
toxic
total
dose
probenecid
given
oral
h
infus
g
h
cidofovir
infus
number
cidofovir
cours
administ
determin
attend
physician
eleven
patient
newli
diagnos
adv
pneumonia
admit
studi
period
nonimmunocompromis
adult
four
patient
fulfil
criteria
sever
communityacquir
pneumonia
improv
clinic
antivir
therapi
exclud
analysi
consequ
seven
patient
sever
adv
pneumonia
analyz
studi
baselin
characterist
shown
tabl
patient
previous
healthi
young
male
without
underli
condit
three
patient
nonsmok
bodi
mass
index
kgm
patient
vari
ill
patient
n
occur
earli
spring
one
occur
winter
three
patient
militari
train
facil
patient
differ
oper
area
patient
present
acut
respiratori
system
symptom
fever
n
cough
n
purul
sputum
n
bloodting
sputum
n
dyspnea
n
one
patient
concurr
upper
respiratori
tract
symptom
three
patient
extrapulmonari
symptom
diarrhea
patient
respiratori
distress
hypoxemia
pao
fio
ratio
mmhg
six
patient
tachycardia
beatsmin
tachypnea
breathsmin
three
patient
need
vasopressor
mechan
ventil
median
durat
onset
symptom
admiss
day
five
patient
receiv
empir
antibiot
includ
quinolon
n
thirdgener
cephalosporin
n
admiss
two
remain
patient
receiv
quinolon
n
identifi
patient
piperacillin
n
identifi
patient
admiss
initi
chest
ct
find
patient
sever
adv
pneumonia
shown
tabl
patient
n
bilater
lobar
consolid
ground
glass
opac
upper
lower
lobe
fig
two
patient
unilater
lobar
consolid
without
ground
glass
opac
commonli
involv
lobe
left
lower
lobe
n
follow
right
lower
lobe
n
left
lower
lobe
n
lower
lobe
n
pleural
effus
observ
patient
result
initi
laboratori
test
shown
tabl
patient
thrombocytopenia
n
patient
leukopenia
none
leukocytosi
creactiv
protein
level
elev
patient
median
mgdl
procalcitonin
level
elev
five
patient
maximum
ngml
hyponatremia
observ
two
patient
patient
elev
liver
enzym
pleural
fluid
analysi
perform
four
patient
result
lymphocytedomin
exud
without
evid
empyema
adv
identifi
patient
pcr
sputum
n
bal
fluid
n
serotyp
sequenc
analysi
avail
six
patient
isol
type
n
human
fig
bacteri
coinfect
identifi
sputum
two
patient
pcr
pneumonia
patient
pneumonia
h
influenza
patient
identifi
caus
agent
identifi
clinic
respons
antivir
therapi
studi
patient
clinic
respons
treatment
patient
shown
fig
fig
show
clinic
respons
patient
need
vasopressor
mechan
ventil
due
septic
shock
sever
respiratori
failur
patient
cidofovir
administr
blood
pressur
stabil
approxim
day
tachypnea
tachycardia
fever
improv
within
day
oxygen
complet
improv
within
day
fig
patient
blood
pressur
stabil
approxim
day
tachypnea
tachycardia
fever
improv
within
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
patient
blood
pressur
stabil
approxim
day
tachypnea
tachycardia
fever
within
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
patient
tachypnea
tachycardia
fever
improv
within
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
patient
tachypnea
tachycardia
fever
improv
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
patient
tachypnea
tachycardia
fever
improv
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
patient
tachypnea
tachycardia
fever
improv
day
oxygen
complet
improv
within
day
cidofovir
administr
fig
overal
treatment
outcom
studi
patient
summar
tabl
median
time
admiss
identif
adv
infect
rang
day
patient
receiv
cidofovir
patient
n
receiv
cidofovir
within
h
minimum
h
median
h
one
patient
receiv
cidofovir
h
admiss
median
time
onset
symptom
cidofovir
administr
day
three
patient
patient
need
vasopressor
mechan
ventil
receiv
two
dose
cidofovir
four
patient
patient
receiv
singl
dose
cidofovir
six
patient
receiv
adjuv
intraven
immunoglobulin
day
cidofovir
administr
clinic
radiolog
laboratori
improv
occur
patient
complet
symptomat
improv
occur
median
rang
day
complet
radiograph
resolut
occur
median
rang
day
fig
normal
white
blood
cell
count
creactiv
protein
level
median
rang
day
rang
day
respect
advers
reaction
skin
rash
cidofovir
occur
one
patient
resolv
complet
conserv
manag
patient
recov
complet
without
complic
present
studi
describ
favor
outcom
antivir
therapi
cidofovir
nonimmunocompromis
adult
patient
sever
adv
pneumonia
data
suggest
earli
administr
cidofovir
cours
respiratori
failur
could
treatment
strategi
worth
consid
sever
adv
pneumonia
seven
case
discuss
cidofovir
administ
promptli
previou
fatal
case
previou
studi
patient
receiv
antivir
therapi
cidofovir
inde
even
patient
receiv
cidofovir
administr
time
earli
cours
respiratori
failur
poor
outcom
exampl
recent
studi
evalu
outcom
five
patient
sever
adv
pneumonia
caus
infect
nonimmunocompromis
adult
similar
studi
group
four
five
patient
die
despit
receiv
appropri
respiratori
support
antivir
therapi
includ
acyclovir
ganciclovir
ribavirin
without
use
cidofovir
studi
etiolog
epidemiolog
acut
viral
lower
respiratori
tract
infect
south
korean
soldier
institut
six
case
sever
adv
pneumonia
identifi
six
patient
requir
mechan
ventil
receiv
cidofovir
half
includ
one
patient
treat
cidofovir
day
admiss
die
moreov
case
report
fatal
adv
pneumonia
immunocompet
adult
ident
twin
one
patient
recov
despit
administr
cidofovir
antivir
therapi
sooner
day
onset
symptom
present
studi
contrast
time
admiss
identif
adv
short
median
day
patient
receiv
antivir
therapi
day
diagnosi
adv
infect
given
background
find
may
indic
administr
cidofovir
earli
cours
respiratori
failur
may
benefici
treatment
strategi
sever
case
adv
respiratori
infect
may
assist
physician
make
decis
regard
diagnosi
treatment
studi
isol
type
n
human
date
human
adv
type
identifi
serotyp
commonli
associ
human
diseas
among
human
identifi
emerg
acut
respiratori
diseas
pathogen
fulli
character
wholegenom
sequenc
caus
two
recent
outbreak
one
china
one
singapor
one
studi
evalu
case
adv
pneumonia
patient
infect
human
higher
pneumonia
sever
index
score
compar
infect
serotyp
thu
human
could
major
pneumonia
pathogen
gener
popul
surveil
monitor
agent
caus
pneumonia
warrant
howev
date
limit
data
correl
human
clinic
sever
clinic
cours
avail
data
avail
treatment
respons
cidofovir
case
human
infect
context
data
may
clinic
signific
studi
associ
adv
serotyp
sever
respiratori
infect
necessari
pathophysiolog
adv
pneumonia
remain
unclear
studi
perform
exampl
princ
et
al
gregori
et
al
indic
much
acut
damag
adenoviru
infect
appear
due
dysregul
immun
system
featur
may
part
explain
selflimit
natur
case
even
sever
adv
infect
without
antivir
therapi
suggest
host
immunolog
reaction
infect
major
factor
pathogenesi
lung
injuri
moreov
impli
antivir
therapi
administ
late
cours
respiratori
failur
may
effect
howev
accur
data
pathophysiolog
adv
studi
need
studi
sever
limit
firstli
studi
control
respect
treatment
administ
retrospect
design
although
obtain
favor
outcom
factor
may
influenc
outcom
studi
patient
support
treatment
strategi
includ
ventil
set
prone
posit
host
factor
includ
young
age
previou
good
health
statu
moreov
selflimit
case
sever
adv
infect
report
previous
date
control
studi
report
benefit
antivir
therapi
sever
adv
pneumonia
may
mainli
rariti
sever
adv
pneumonia
nonimmunocompromis
adult
ethic
problem
use
antivir
agent
obvious
demonstr
clinic
effect
context
data
despit
limit
may
suggest
possibl
benefit
administ
cidofovir
earli
possibl
sever
adv
pneumonia
caus
mainli
human
base
clinic
data
control
studi
warrant
confirm
benefit
cidofovir
second
despit
extens
microbiolog
test
possibl
influenc
bacteri
coinfect
treatment
outcom
exclud
furthermor
studi
includ
small
number
patient
addit
studi
popul
repres
gener
popul
term
age
gender
studi
conduct
militari
hospit
thu
larg
prospect
studi
need
describ
favor
clinic
outcom
antivir
therapi
cidofovir
nonimmunocompromis
adult
patient
sever
adv
pneumonia
data
suggest
earli
administr
cidofovir
cours
treatment
respiratori
failur
result
adv
pneumonia
nonimmunocompromis
patient
could
treatment
strategi
worth
consid
especi
case
infect
